HealthBlawg

David Harlow's Health Care Law Blog

  • About
  • Archives
  • Podcast
  • Press
  • Awards/Reviews
  • HIPAA
  • HCSM

To negotiate or not to negotiate – That is the Medicare drug benefit question

January 2, 2007

One of the Democrats’ "first 100 hours" issues seems to be repeal of the ban on Medicare negotiation of drug prices. 

That’s a good thing.

The N.Y. Times reports today that acting CMS administrator Leslie Norwalk

said that under the Democrats’ proposal her agency would have to “hire hundreds of people to negotiate prices for 4,500 different drugs.” And Ms. Norwalk said the agency would be besieged by lobbyists seeking higher Medicare payments for specific drugs. That, she said, is “how Washington really works.”

I’d call that a copout.   

Remember, her colleagues in the Bush Administration misled Congress when they projected the ten-year cost of the Medicare drug benefit to be $400 billion.  (It will cost $1 trillion; that’s how Washington really works.)  So she can afford to hire a couple hundred employees — not that it should take that many — and still come out ahead.  A one percent savings off the lowball estimate ($4 billion) dwarfs the alarmist supposed cost of administering this program (let’s call it $250 million over ten years if it takes 250 $100,000-a-year employees to do the job).  If we use the current cost estimate, a 1% "shave" for Big Pharma would yield savings of $10 billion.

Yes, Virginia, there are transaction costs inherent in our inefficient health care system, and we have to make sure the savings don’t land in the pockets of the benefit plan administrators, but there’s no excuse for failing to use the market power of the federal government in negotiating drug prices.

Other issues on the agenda include looosening restrictions on federally-funded stem cell research.  The Times article continues:

Lawmakers are also likely to wrestle with these issues:

¶Many Democrats will try to reduce Medicare payments to managed care plans. They contend such plans are overpaid by about 10 percent. Insurers intend to fight back, with support from the Bush administration, Republican lawmakers and beneficiaries who see the plans as a way to obtain extra benefits at an affordable cost.

¶Congress faces a huge challenge in devising a new formula to pay doctors for treating Medicare patients. Under the current formula, doctors’ fees would be cut more than 4 percent a year for the next decade. Lawmakers are determined to avert such cuts, but see no easy way to pay the cost.  [See earlier HealthBlawg posts on this issue here and here.]

¶Democrats have drafted legislation to speed the approval of safe, low-cost versions of expensive biotechnology drugs, which account for a growing share of spending on pharmaceuticals.

Stay tuned.

— David Harlow

Related Posts

  • Is Medicare Part D working?

    According to the pharmacy benefit managers' trade association:Medicare prescription drug plans (PDPs) achieved higher-than-expected savings…

  • Medicare fraud attracts South Florida drug traffickers

    Here's the lead from today's Morning Edition story on Medicare fraud:There's a nationwide crime epidemic…

  • First 100 hours agenda item - House passes Medicare prescription drug negotiation requirement

    The House of Representatives has passed part of the Democrats' "first hundred hours" agenda (follow…

Filed Under: CMS, Health Law, Medicare

« Health care insurance reform notes from South Carolina
HIPAA security guidance for off-site use of electronic protected health information (EPHI) »

Threads

Follow me on: Threads

Mastodon

Follow me on: Mastodon

HIPAAtools

Hipaatools

The HIPAA Compliance Toolkit

The Walking Gallery

The Walking Gallery

Quick Links

  • Home
  • Categories
  • Archives
  • Podcast Interviews
  • HIPAAtools
  • HIPAA Compliance
  • Health Care Social Media
  • Speaking
  • In the Press
  • Blogroll

David Harlow

David Harlow

HealthcareNOW Radio

  • Subscribe
  • Contact
  • Book Me: Speaking
  • About
  • The Harlow Group LLC
Copyright © 2006–2025
HealthBlawg is a publication of The Harlow Group LLC. See Copyright notice and disclaimer.
Fair use with attribution and a link is encouraged. Click for more on David Harlow.
[footer_backtotop text="Back to top" href="#"]